Ipamorelin is a growth hormone secretagogue (GHS) peptide that stimulates the release of growth hormone from the anterior pituitary gland. It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Ipamorelin was derived from GHRP-1, another GHS peptide.
Ipamorelin is different from other GHS peptides in a few ways. First, it is more selective for the growth hormone-releasing hormone (GHRH) receptor, which means that it is less likely to cause other side effects, such as increased cortisol levels. Second, ipamorelin has a longer half-life, which means that it can be administered less frequently.
Ipamorelin is currently being investigated for the treatment of a variety of conditions, including:
- Growth hormone deficiency
- Muscle wasting
- Osteoporosis
- Diabetes
- Heart disease
- Stroke
- Alzheimer’s disease
Ipamorelin is not yet approved by the US Food and Drug Administration (FDA) for any use. It is considered an investigational drug and is only available through clinical trials.
How is ipamorelin peptide used?
Ipamorelin is typically administered by injection. It can be injected subcutaneously (under the skin) or intramuscularly (into the muscle). Ipamorelin is typically injected three times per day, but the exact dosage and schedule will vary depending on the individual’s condition.
Potential benefits of ipamorelin peptide
Ipamorelin has been shown to have a number of potential benefits, including:
- Increased growth hormone levels
- Increased muscle mass and strength
- Improved bone density
- Improved glucose control
- Improved heart function
- Improved cognitive function
Potential side effects of ipamorelin peptide
Ipamorelin is generally well-tolerated, but it can cause some side effects, such as:
- Headache
- Nausea
- Vomiting
- Muscle cramps
- Joint pain
- Fluid retention
Ipamorelin should not be used by people who have cancer, are pregnant or breastfeeding, or have diabetes. It should also not be used by people who are taking certain medications, such as insulin or corticosteroids.
Ipamorelin is a promising new therapy for a variety of conditions. It is important to note that ipamorelin is an investigational drug and is not yet approved by the US Food and Drug Administration (FDA) for any use. More research is needed to determine the long-term safety and efficacy of ipamorelin therapy.
If you are interested in learning more about ipamorelin, talk to your doctor.
